Oral Oncolytics Will Require Health Care System to Adapt
Judging from the drug pipeline, the future of oncology is oral chemotherapy.
Investigators Take Aim at GBM With a Biomarker-Driven Approach
Efforts are underway to expedite the identification of therapies that offer promise for patients with glioblastoma
Biosimilars Expand Patient Access to Novel Treatments
A panel of hematology-oncology experts discuss the emergence of biosimilar use in oncology.
CLR 131 Leads a New Generation of Lipid-Based Cancer Drug Delivery Systems
A novel compound that uses abundant lipids in cancer cell membranes to deliver a radioisotope to the tumor environment shows early signs of efficacy in a range of B-cell malignancies.
UGN-102 Emerges As Potential Surgical Alternative for Low-Grade, Intermediate-Risk NMIBC
Primary chemoablation with UGN-102 elicited encouraging responses in patients with low-grade, intermediate-risk non–muscle-invasive bladder cancer and may consequently be an appropriate nonsurgical treatment intervention for patients.
CAR T Pioneers Describe Challenges Faced in Cancer
Advances of chimeric antigen receptor T-cell therapy technologies are in rapid development and under investigation in a range of preclinical and clinical research around the globe.
Ramucirumab Combination Expands Lung Cancer Options
Edgardo Santos, MD, discusses the FDA approval of ramucirumab plus erlotinib for the first-line treatment of patients with metastatic NSCLC with EGFR exon 19 deletions
or exon 21 (L858R) mutations.
Three Key ASCO Studies Showcase Targeted Advances
Molecularly targeted therapies showed practice-changing results for patients with biomarker-driven lung, colorectal, and ovarian cancers in phase 3 randomized clinical trial findings.
New Indication Propels Brigatinib Into the Front Line for ALK-Positive NSCLC
Thomas E. Stinchcombe, MD, discusses brigatinib’s mechanism as well as the next steps to advance the treatment paradigm for patients with ALK-positive NSCLC.
Patient Outcomes Support Cabazitaxel Over Standard in mCRPC
Findings from a preplanned analysis of the phase 4 CARD study demonstrated superior patient-reported outcomes with cabazitaxel in men with castration-resistant prostate cancer who received prior docetaxel and androgen receptor targeted therapy versus alternative AR-targeted treatment options.
Public Mistrust May Undermine HPV and COVID-19 Vaccines
These are disquieting times for clear and decisive messaging regarding vaccines.
Racial Disparity Revealed in Prometastatic TME in Women With Residual Breast Cancer After Neoadjuvant Chemo
Sotigalimab/Pembrolizumab Combo Continues to Show Clinical Activity in Frontline Melanoma
Dr. Halmos on Trastuzumab Deruxtecan in NSCLC
Dr. Kris on Immunotherapy in NSCLC Without Driver Mutations
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.